Colgate-Palmolive Company
CL
$88.27
-0.18%
Colgate-Palmolive Company is a global leader in the Household & Personal Products industry, manufacturing and selling a wide range of consumer goods including oral care (its namesake Colgate brand), personal care, home care, and pet nutrition through its Hill's brand. The company is a dominant market player with a vast international footprint, deriving about 70% of its sales from outside the U.S. and nearly half from emerging markets, which provides a stable, defensive revenue base. The current investor narrative revolves around its role as a classic defensive stock during market rotations, with recent news highlighting a shift from growth to value, and debates center on its ability to sustain growth and margins amid inflationary pressures while leveraging its strong brand portfolio and geographic diversification.…
CL
Colgate-Palmolive Company
$88.27
Investment Opinion: Should I buy CL Today?
Rating & Thesis: Hold. Colgate-Palmolive is a high-quality, defensive staple with exceptional profitability, but its premium valuation and modest growth profile limit near-term upside, making it suitable for income-focused investors but not an aggressive buy. This aligns with the mixed analyst consensus of Buy, Overweight, and Hold ratings, with an implied average target based on forward EPS estimates.
Supporting Evidence: The stock's forward P/E of 22.3x is elevated for the sector, though it represents a discount to its distorted trailing P/E of 30.0x. Revenue growth is positive but modest at 5.78% YoY, and the company demonstrates superior profitability with a 39.48% ROE and 10.46% net margin. Strong free cash flow generation of $3.63 billion TTM supports the sustainable 2.85% dividend yield. The implied upside from the current price to a target derived from the average analyst EPS estimate of $4.85 and a 22.3x multiple is minimal, suggesting fair valuation.
Risks & Conditions: The two biggest risks are valuation compression from its high multiples and earnings volatility from its leveraged balance sheet. This Hold rating would upgrade to a Buy if the forward P/E compressed below 20x without a deterioration in the 5%+ revenue growth trajectory, or if the stock approached its 52-week low of $74.55, offering a more compelling margin of safety. It would downgrade to a Sell if revenue growth decelerated below 3% YoY or if net margins contracted significantly from the current 10.46%. The stock is currently fairly valued relative to its own growth prospects and defensive profile.
Sign up to view all
CL 12-Month Price Forecast
Colgate-Palmolive is a high-quality company stuck in a fair valuation zone. Its defensive attributes (low beta, reliable dividend) are balanced against a premium multiple and modest growth trajectory, leading to a neutral stance. The base case (60% probability) of range-bound trading between $95 and $100 is most likely, as the stock digests its recent rally and awaits clearer evidence of earnings acceleration. The stance would upgrade to bullish if revenue growth sustainably accelerates above 7% or if the multiple contracts to below 20x forward P/E on a market pullback. It would turn bearish if quarterly revenue growth falls below 3% or if operating margins show sustained contraction.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Colgate-Palmolive Company's 12-month outlook, with a consensus price target around $114.75 and implied upside of +30.0% versus the current price.
Average Target
$114.75
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$71 - $115
Analyst target range
Analyst coverage for this large-cap staple is extensive, with recent institutional ratings from major firms like Deutsche Bank, Barclays, and Citigroup. The consensus sentiment leans bullish to neutral, with a mix of Buy, Overweight, and Hold ratings, reflecting confidence in the company's defensive qualities and stable cash flows but also acknowledging its mature growth profile. The average analyst revenue estimate for the coming year is $24.25 billion, with a tight EPS estimate range between $4.73 and $4.94, indicating strong agreement on the company's near-term financial trajectory. The wide target price range implied by the high and low EPS estimates signals some underlying uncertainty, likely related to the pace of margin recovery post the Q4 charge and the impact of foreign exchange on international earnings, which is a key risk given 70% of sales are overseas.
Bulls vs Bears: CL Investment Factors
The bull case for Colgate-Palmolive is anchored in its defensive characteristics, exceptional profitability (39.48% ROE), and strong cash generation supporting a reliable dividend. The bear case focuses on its premium valuation, high financial leverage, and chronic market underperformance. Currently, the bull side holds stronger evidence for investors seeking capital preservation and income, given its low volatility (beta 0.30) and robust fundamentals. The single most important tension in the investment debate is whether the company's premium valuation (forward P/E 22.3x) is justified by its modest revenue growth (5.78% YoY) or if it represents an overpayment for stability, leaving the stock vulnerable to multiple compression if growth disappoints.
Bullish
- Exceptional Profitability & Efficiency: The company generates an exceptionally high Return on Equity of 39.48%, far exceeding typical industry standards, demonstrating superior capital efficiency. This is supported by a robust trailing twelve-month net margin of 10.46% and a strong gross margin of 60.15%, indicating pricing power and cost control.
- Defensive Profile & Low Volatility: With a beta of 0.30, CL exhibits less than a third of the market's volatility, making it a classic defensive holding. This characteristic is highly valued during market rotations from growth to value, as evidenced by recent news, and provides stability for risk-averse portfolios.
- Strong Cash Generation & Dividend: The company generates substantial free cash flow of $3.63 billion TTM, supporting its shareholder returns. It maintains a dividend yield of 2.85% with a high payout ratio of 85.5%, appealing to income-focused investors seeking reliable yield from a stable business.
- Analyst Confidence in Forward Earnings: Analysts project forward EPS of $4.85, implying a forward P/E of 22.3x, a significant discount to the trailing P/E of 30.0x. This suggests the market expects a strong earnings recovery from the Q4 2025 net loss, which was driven by a one-time $970 million charge.
Bearish
- Elevated Valuation Multiples: The stock trades at a premium with a forward P/E of 22.3x and an EV/EBITDA of 17.85x, which are high for the consumer staples sector. The trailing P/E of 30.0x, though distorted by the Q4 charge, still indicates limited room for multiple expansion from current levels.
- High Financial Leverage: A debt-to-equity ratio of 147.93% indicates significant financial leverage, which increases risk in a rising interest rate environment. While strong cash flow mitigates this, it limits financial flexibility and could pressure earnings if refinancing costs rise.
- Recent Earnings Volatility & Growth Deceleration: Q4 2025 reported a net loss of -$37 million due to a large one-time charge, highlighting potential earnings volatility. Furthermore, sequential quarterly revenue growth has decelerated from Q1/Q2 2025, suggesting underlying top-line momentum may be slowing.
- Chronic Market Underperformance: The stock has significantly underperformed the broader market, with a -30.56% 1-year relative strength versus the SPY. This long-term trend suggests the market has been discounting its slower growth profile compared to other sectors, a headwind for total returns.
CL Technical Analysis
The stock is in a sustained uptrend over the past six months, evidenced by a 12.12% gain, but has recently experienced a pullback from its highs, trading 9.27% below its 52-week high of $99.33. Currently priced at $90.13, the stock sits approximately 60% of the way up from its 52-week low of $74.55, indicating it is in the upper-mid range of its annual band, suggesting momentum has cooled but the longer-term uptrend remains intact. Recent momentum shows a divergence, with a strong 6.68% gain over the past month contrasting with a 9.09% decline over the past three months, signaling a potential recovery from a sharp Q1 2026 sell-off; this is supported by a positive 1-month relative strength of 0.37% versus the SPY, though the stock remains a significant long-term underperformer with a -30.56% 1-year relative strength. Key technical levels are clearly defined with support at the 52-week low of $74.55 and resistance at the 52-week high of $99.33; a breakout above $99.33 would signal a resumption of the powerful uptrend that peaked in February, while a breakdown below $74.55 would indicate a major trend failure. The stock's low beta of 0.30 confirms its defensive, low-volatility characteristics, meaning it typically exhibits less than a third of the market's swings, which is crucial for risk-averse portfolios but also implies limited participation in strong bull markets.
Beta
0.30
0.30x market volatility
Max Drawdown
-19.7%
Largest decline past year
52-Week Range
$75-$99
Price range past year
Annual Return
-4.0%
Cumulative gain past year
| Period | CL Return | S&P 500 |
|---|---|---|
| 1m | +1.2% | +5.4% |
| 3m | -7.4% | +10.9% |
| 6m | +13.8% | +11.0% |
| 1y | -4.0% | +28.1% |
| ytd | +13.6% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CL Fundamental Analysis
Revenue growth remains positive but modest, with Q4 2025 revenue of $5.23 billion representing a 5.78% year-over-year increase; however, examining sequential quarters reveals a trend of deceleration from stronger growth earlier in the year, as Q3 2025 revenue was $5.13 billion and Q2 was $5.11 billion. Segment data shows the core Oral, Personal and Home Care segment generated $4.03 billion in the latest period, while the faster-growing Pet Nutrition segment contributed $1.20 billion, indicating a balanced portfolio but overall top-line growth that is steady rather than explosive. The company is highly profitable with a strong gross margin of 60.15% in Q4 2025, though net income for that quarter was an unusual loss of -$37 million, primarily due to a significant $970 million charge in 'total other income expenses net'; excluding this, operating income was a robust $1.08 billion, representing a 21.33% operating margin. Over the trailing twelve months, the company maintains a healthy net margin of 10.46% and an impressive return on equity of 39.48%, demonstrating exceptional efficiency in generating profits from shareholder capital, which is well above typical industry standards for consumer staples. The balance sheet carries a high degree of financial leverage with a debt-to-equity ratio of 147.93%, which elevates risk but is partially offset by strong and consistent cash generation, evidenced by trailing twelve-month free cash flow of $3.63 billion and a current ratio of 1.00, indicating adequate short-term liquidity to meet obligations.
Quarterly Revenue
$5.2B
2025-12
Revenue YoY Growth
+0.05%
YoY Comparison
Gross Margin
+0.60%
Latest Quarter
Free Cash Flow
$3.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CL Overvalued?
Given the company's consistent profitability, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE is 29.97x, while the forward PE is lower at 22.30x, indicating the market expects earnings growth to accelerate, which aligns with analyst EPS estimates averaging $4.85 for the coming year. Compared to its own historical range, the current trailing PE of 29.97x is below the extreme highs seen in recent quarters (e.g., 350+ in Q4 2024) but remains elevated compared to longer-term norms, suggesting the stock is not cheap but also not at peak historical valuation optimism. The stock trades at a premium to typical consumer defensive multiples, as evidenced by a Price-to-Sales ratio of 3.14x and an EV/EBITDA of 17.85x; this premium is likely justified by the company's superior brand equity, high returns on equity (39.48%), and consistent dividend payer status in a sector valued for stability, though it leaves little room for multiple expansion.
PE
30.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -430x~3280x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Colgate-Palmolive carries significant financial leverage with a debt-to-equity ratio of 147.93%, which elevates interest rate risk and could pressure net income if borrowing costs remain elevated. While the company maintains strong gross margins of 60.15%, its Q4 2025 net loss of -$37 million, driven by a $970 million one-time charge, exposes earnings to potential volatility from non-operating items. Revenue concentration is not a major issue due to geographic diversification, but the modest 5.78% YoY growth rate may struggle to justify its premium valuation if it decelerates further.
Market & Competitive Risks: The stock trades at a premium valuation with a forward P/E of 22.3x and EV/EBITDA of 17.85x, creating risk of multiple compression if investor sentiment shifts away from defensive staples or if growth disappoints. Its low beta of 0.30, while defensive, also means it has significantly underperformed the market by -30.56% over the past year, indicating sector rotation risk. Competitive pressures in both oral care and pet nutrition could intensify, potentially eroding the high margins that support its current valuation.
Worst-Case Scenario: The most damaging scenario would involve a combination of sustained inflation squeezing gross margins below 60%, a recession in key emerging markets (which contribute nearly half of sales), and a rise in interest rates that significantly increases the cost of its high debt load. This could trigger multiple compression towards historical lows and a growth scare, driving the stock down to its 52-week low of $74.55. From the current price of $90.13, this represents a realistic downside of approximately -17.3%.
FAQ
The key risks are, in order of severity: 1) Valuation Risk: Trading at a forward P/E of 22.3x, the stock is vulnerable to multiple compression if growth slows or investor sentiment shifts. 2) Financial Leverage Risk: A high debt-to-equity ratio of 147.93% increases sensitivity to rising interest rates, which could pressure net income. 3) Operational Risk: Persistent inflation could compress its strong 60.15% gross margin if pricing power wanes. 4) Market Risk: The stock has significantly underperformed the S&P 500 over one year (-30.56% relative strength), indicating sector rotation risk if markets remain bullish on growth.
The 12-month forecast for CL is a range-bound outcome with a base case target of $95-$100 (60% probability), a bull case of $105-$110 (25% probability), and a bear case of $74-$80 (15% probability). The base case, which is most likely, assumes the company meets analyst EPS estimates of ~$4.85, maintains its current valuation multiple (~22x forward P/E), and delivers steady low-single-digit revenue growth. The key assumption is that the company's defensive qualities and high profitability justify its current premium, preventing significant multiple expansion or contraction. The forecast is heavily influenced by the stock's low beta (0.30), which suggests it will largely ignore broad market swings and trade on its own fundamentals.
CL stock is fairly valued relative to its own prospects but trades at a premium to broader market and some sector peers. Its forward P/E of 22.3x is elevated for a company with ~6% revenue growth, though it is justified by its exceptional profitability (39.48% ROE), defensive characteristics, and consistent dividend. Compared to its own history, the trailing P/E of 30.0x is distorted by a one-time charge; the forward multiple is more representative. The EV/EBITDA of 17.85x and Price/Sales of 3.14x also indicate a quality premium. The valuation implies the market is paying for stability and high returns on capital, not for high growth, leaving it fairly priced but not cheap.
CL is a good buy for a specific type of investor: those seeking a low-volatility, defensive holding with a reliable dividend. For total return seekers, it is less compelling. The stock offers a 2.85% dividend yield supported by strong $3.63B annual free cash flow, and its beta of 0.30 provides portfolio stability. However, with a forward P/E of 22.3x and modest ~6% revenue growth, its valuation leaves little room for error. The biggest downside risk is multiple compression if growth disappoints, potentially driving the stock towards its 52-week low of $74.55 (-17% downside). It is a good buy for income-focused, conservative investors but is fairly valued for others.
CL is unequivocally suitable for long-term investment, not short-term trading. As a mature, defensive consumer staples company with modest growth, its value proposition is stability, reliable income, and capital preservation over time. Its low beta of 0.30 means it lacks the volatility typically sought by short-term traders. The sustainable 2.85% dividend yield and high payout ratio (85.5%) are designed for compounding returns over years. A minimum holding period of 3-5 years is suggested to ride out market cycles and fully benefit from the dividend reinvestment and the company's steady, if unspectacular, earnings growth. Short-term investors would likely find better opportunities elsewhere.
